Centre for Reproduction and Genomics, AgResearch Limited, Invermay Animal Research Centre, Puddle Alley, Private Bag 50034, Mosgiel 9053, New Zealand.
Reproduction. 2011 Oct;142(4):565-72. doi: 10.1530/REP-11-0126. Epub 2011 Jul 20.
Sheep with a heterozygous inactivating mutation in the bone morphogenetic protein 15 (BMP15) gene experience an increased ovulation rate during either a natural oestrous cycle or a cycle in which exogenous FSH and eCG (gonadotrophins) are given to induce multiple ovulations. The primary aim of these studies was to determine whether ewes immunised against BMP15 would also show an improved superovulation rate following exogenous gonadotrophin treatment. A secondary aim was to determine the effects of BMP15 immunisation on ovarian follicular characteristics. In most ewes (i.e. > 75%) immunised with a BMP15-keyhole limpet haemocyanin peptide in an oil-based adjuvant in order to completely neutralise BMP15 bioactivity, there was no superovulation response to exogenous gonadotrophins. In ewes treated with exogenous gonadotrophins following a BMP15-BSA peptide immunisation in a water-based adjuvant to partially neutralise BMP15 bioactivity, the ovulation rate response was similar to the control superovulation treatment groups. Characterisation of follicular function revealed that the water-based BMP15-immunised animals had fewer non-atretic follicles 2.5-3.5 or > 4.5 mm in diameter compared with controls. Basal concentrations of cAMP were higher in granulosa cells from animals immunised against BMP15 than control animals. There were no significant differences in the concentrations of cAMP between granulosa cells from BMP15- and control-immunised animals when given FSH or hCG, although there were differences in the proportions of follicles in different size classes that responded to FSH or hCG. Thus, immunisation against BMP15 may have been causing premature luteinisation and thereby limiting the numbers of follicles recruited for ovulation following treatment with exogenous gonadotrophins.
携带骨形态发生蛋白 15(BMP15)基因杂合失活突变的绵羊,无论是在自然发情周期还是在外源性促卵泡激素(FSH)和促性腺激素释放激素(eCG)诱导多次排卵的周期中,排卵率都会增加。这些研究的主要目的是确定针对 BMP15 进行免疫的母羊在接受外源性促性腺激素治疗后是否也会表现出更好的超排卵率。次要目的是确定 BMP15 免疫对卵巢卵泡特征的影响。在大多数用 BMP15-血蓝蛋白钥孔戚血蓝蛋白肽在油基佐剂中免疫的母羊(即>75%)中,完全中和 BMP15 的生物活性,对外源促性腺激素没有超排卵反应。在用基于水的佐剂中的 BMP15-BSA 肽免疫部分中和 BMP15 的生物活性后,用外源促性腺激素处理的母羊中,排卵率反应与对照超排卵处理组相似。卵泡功能特征表明,与对照组相比,基于水的 BMP15 免疫动物的 2.5-3.5 毫米或>4.5 毫米直径的非闭锁卵泡较少。针对 BMP15 进行免疫的动物的颗粒细胞中的 cAMP 基础浓度高于对照动物。用 FSH 或 hCG 处理时,BMP15 和对照免疫动物的颗粒细胞中的 cAMP 浓度没有显著差异,尽管在对外源 FSH 或 hCG 有反应的不同大小类别的卵泡比例上存在差异。因此,针对 BMP15 的免疫可能导致过早的黄体化,从而限制了在外源性促性腺激素治疗后排卵募集的卵泡数量。